STELLA PHARMA CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 305 JPY | +1.33% |
|
+2.35% | +7.02% |
| 02-13 | Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024 | CI |
| 2023 | Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024 | CI |
Valuation
| Fiscal Period: March | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 17,281 | 11,485 |
| Enterprise Value (EV) 1 | 15,258 | 9,868 |
| P/E ratio | -22.1 x | -14.4 x |
| Yield | - | - |
| Capitalization / Revenue | 172,814,976 x | 50,153,579 x |
| EV / Revenue | 152,584,976 x | 43,092,444 x |
| EV / EBITDA | -21,582,033 x | -12,799,182 x |
| EV / FCF | -18,428,137 x | -17,343,005 x |
| FCF Yield | -0% | -0% |
| Price to Book | 5.61 x | 4.15 x |
| Nbr of stocks (in thousands) | 28,659 | 29,677 |
| Reference price 2 | 603.0 | 387.0 |
| Announcement Date | 22-06-30 | 23-06-28 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales | - | - | 205 | 100 | 229 |
| EBITDA | - | - | -650 | -707 | -771 |
| EBIT 1 | -861 | -951 | -681 | -741 | -806 |
| Operating Margin | - | - | -332.2% | -741% | -351.97% |
| Earnings before Tax (EBT) 1 | -857 | -960 | -657 | -764 | -776 |
| Net income 1 | -859 | -962 | -659 | -767 | -778 |
| Net margin | - | - | -321.46% | -767% | -339.74% |
| EPS 2 | -66.28 | -61.67 | -32.89 | -27.31 | -26.94 |
| Free Cash Flow | - | - | -571.5 | -828 | -569 |
| FCF margin | - | - | -278.78% | -828% | -248.47% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 21-03-19 | 21-03-19 | 21-06-30 | 22-06-30 | 23-06-28 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: |
|---|
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | 162 | - | - |
| Net Cash position 1 | 1,391 | 434 | - | 2,023 | 1,617 |
| Leverage (Debt/EBITDA) | - | - | -0.2492 x | - | - |
| Free Cash Flow | - | - | -572 | -828 | -569 |
| ROE (net income / shareholders' equity) | - | -82.2% | -143% | -46.4% | -26.7% |
| ROA (Net income/ Total Assets) | - | -18.9% | -18.1% | -13.7% | -11.1% |
| Assets 1 | - | 5,083 | 3,645 | 5,603 | 6,986 |
| Book Value Per Share 2 | 127.0 | 44.20 | 11.40 | 107.0 | 93.40 |
| Cash Flow per Share 2 | 231.0 | 129.0 | 62.10 | 114.0 | 91.90 |
| Capex | - | - | 21 | 46 | 26 |
| Capex / Sales | - | - | 10.24% | 46% | 11.35% |
| Announcement Date | 21-03-19 | 21-03-19 | 21-06-30 | 22-06-30 | 23-06-28 |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +7.02% | 60.84M | |
| +32.91% | 700B | |
| -4.82% | 358B | |
| +19.64% | 330B | |
| +3.94% | 287B | |
| +16.09% | 236B | |
| +6.67% | 202B | |
| -9.12% | 197B | |
| +4.35% | 161B | |
| -3.30% | 157B |
- Stock Market
- Equities
- 4888 Stock
- Financials Stella Pharma Corporation